Lisata Q1 net loss $6.2M; cash $61.1M; LSTA1 advances but LSTA201 disappoints

LISATA THERAPEUTICS, INC.

2023-Q1 EPS reported -$0.77

Q1 net loss $6.2M vs $4.2M YoY; R&D $3.2M, G&A $3.7M.
Cash, equivalents & marketable securities $61.1M as of Mar 31; plus $2.2M non-dilutive NJ tax credit received Q2.
LSTA1: first patient dosed in iLSTA trial for pancreatic cancer; basket trial in solid tumors planned before end of Q2 2023.
LSTA201 for diabetic kidney disease showed safety but no consistent kidney function improvement; development only with partner.
HONEDRA (LSTA12) for critical limb ischemia in Japan: pre-consultation with PMDA; seeking partner.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LISATA THERAPEUTICS, INC. reported financial results for the three months ended March 31, 2023.

Period: the three months ended March 31, 2023
Result: reported results

Exact text from the filing

Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

View on SEC.gov

Browse all earnings releases →

LISATA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000320017-23-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.